GlassScriptPhysician profile
Susan D Weigel
NPI 1841262250
$947.57
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $166 · 2022: $55.44 · 2023: $368 · 2024: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $203.31 | 2023 | Camzyos |
| Boston Scientific Corporation | $125.30 | 2021-2024 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $122.58 | 2021 | |
| Philips North America LLC | $122.55 | 2024 | (9520) Igt Devices Undivided |
| Lexicon Pharmaceuticals, INC. | $116.10 | 2024 | Inpefa |
| Medtronic, INC. | $57.64 | 2024 | Micra, Selectsecure |
| Astrazeneca Pharmaceuticals LP | $44.22 | 2023-2024 | Wainua, Farxiga |
| Abbott Laboratories | $38.25 | 2022-2023 | Mitraclip |
| Atricure, INC. | $32.49 | 2023 | |
| Novartis Pharmaceuticals Corporation | $32.11 | 2023 | |
| Novo Nordisk INC | $22.12 | 2023 | Ozempic |
| Merck Sharp & Dohme LLC | $15.93 | 2023 | Verquvo |
| Pfizer INC. | $14.97 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Weigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.